SAN DIEGO, Jun 07, 2010 (BUSINESS WIRE) --Illumina, Inc. (NASDAQ:ILMN) announced today that the Broad Institute has purchased 51 HiSeq 2000s, Illumina's market leading high-throughput next-generation sequencing system. The HiSeq 2000s will replace an equal number of Genome AnalyzerIIx systems in the current installed base as the Broad upgrades and expands its sequencing capacity.
"We believe that the HiSeq 2000s will significantly increase our capabilities in high-throughput genomics, as our experience with early access instruments has already produced multiple runs in excess of 250 Gb of data and yielded significant improvements in lab workflow," said Robert Nicol, Ph.D., director of Sequencing Operations and Technology Development at the Broad Institute. "Coupled with Illumina's newest sequencing chemistry, the system has the potential to increase high-quality base yields at longer read lengths, and could help improve mapping accuracy and variant discovery."
The application flexibility, ease of use and scalability of the HiSeq 2000 enables a wide range of biomedical applications. The compatibility of HiSeq 2000 sample preparation and data analysis with that of the Genome AnalzyerIIxsystem allows organizations like the Broad Institute to seamlessly introduce the HiSeq systems into their existing sequencing infrastructures. The 51 HiSeq 2000s will be shipped to the Broad over the next several quarters.
"We are absolutely delighted that the Broad Institute has elected to continue to scale its sequencing operations with Illumina," said Matt Posard, vice president of Worldwide Sales at Illumina. "The Broad has long been a supporter of Illumina's Sequencing by Synthesis (SBS) chemistry via its installed base of Genome Analyzers and now with the HiSeq 2000. This purchase validates the ongoing improvements Illumina has made to the SBS workflow and is testament to the ease of use and significant throughput benefits enabled by the HiSeq 2000."
The HiSeq 2000 sequencing system offers unprecedented output and a breakthrough user experience. Leveraging Illumina's proven and widely-adopted, reversible terminator-based SBS chemistry in combination with innovative engineering, HiSeq 2000 delivers the industry's highest sequencing output and fastest data generation rate. Internal HiSeq 2000 runs have already yielded throughput well over 350 Gb with unprecedented accuracy and number of perfect reads. Human interaction design features and the easiest sequencing workflow set a new standard for simplicity and user experience. For more information about the HiSeq 2000 sequencing system, please visit Illumina's website at http://illumina.com/HiSeq2000.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which can enhance drug discovery and clinical research, allow diseases to be detected earlier, and may eventually permit better choices of drugs for individual patients.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements that are not statements of historical fact. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen, 858-202-4507
Sr. Director, Investor Relations
pfromen@illumina.com
or
Media:
Wilson Grabill, 858-882-6822
Senior Manager, Public Relations
wgrabill@illumina.com
